Market closed
Akero Therapeutics/AKRO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Akero Therapeutics
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
Ticker
AKRO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
61
Website
AKRO Metrics
BasicAdvanced
$2B
Market cap
-
P/E ratio
-$3.40
EPS
-0.26
Beta
-
Dividend rate
Price and volume
Market cap
$2B
Beta
-0.26
52-week high
$37.00
52-week low
$11.25
Average daily volume
513K
Financial strength
Current ratio
24.893
Quick ratio
24.386
Long term debt to equity
4.466
Total debt to equity
4.5
Interest coverage (TTM)
-58.44%
Management effectiveness
Return on assets (TTM)
-19.15%
Return on equity (TTM)
-28.87%
Valuation
Price to book
2.49
Price to tangible book (TTM)
2.49
Price to free cash flow (TTM)
-8.984
Growth
Earnings per share change (TTM)
35.85%
3-year earnings per share growth (CAGR)
7.36%
What the Analysts think about AKRO
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Akero Therapeutics stock.
AKRO Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AKRO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AKRO News
AllArticlesVideos
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
GlobeNewsWire·6 days ago
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference
GlobeNewsWire·4 weeks ago
Akero Therapeutics: Good Candidate For The MASH Basket
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Akero Therapeutics stock?
Akero Therapeutics (AKRO) has a market cap of $2B as of October 26, 2024.
What is the P/E ratio for Akero Therapeutics stock?
The price to earnings (P/E) ratio for Akero Therapeutics (AKRO) stock is 0 as of October 26, 2024.
Does Akero Therapeutics stock pay dividends?
No, Akero Therapeutics (AKRO) stock does not pay dividends to its shareholders as of October 26, 2024.
When is the next Akero Therapeutics dividend payment date?
Akero Therapeutics (AKRO) stock does not pay dividends to its shareholders.
What is the beta indicator for Akero Therapeutics?
Akero Therapeutics (AKRO) has a beta rating of -0.26. This means that it has an inverse relation to market volatility.